No profile data available.
Cullinan Therapeutics, Inc. (CGEM) is a healthcare company in the additional cancer treatment drugs industry, based in Cambridge, United States, with about 109 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$219.88 million. Its market capitalization was $999.43 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
Cullinan Therapeutics reported $0 in revenue for fiscal year 2025.
$999.43 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Janux Therapeutics, Inc. (JANX), Oric Pharmaceuticals, Inc. (ORIC), Adlai Nortye Ltd. (ANL), Replimune Group, Inc. (REPL).